Concepedia

Author

Adrian D. Hrabar

Harvard University

Also Known As

A Hrabar, A. D. Hrabar, A. Hrabar, A.D. Hrabar, ADRIAN HRABAR, Adrian D Hrabar, Adrian D. Hrabar, Adrian Hrabar, Adrián Hrabar, Horacio O. Jure

28

Publications

6.2K

Citations

16

H-Index

29

Concepts

All Affiliations

Harvard UniversityMcMaster UniversityUniversity of EdinburghPopulation Health Research InstituteInstituto Dante Pazzanese de Cardiologia
AD

About

Adrian D. Hrabar is an author at Harvard University specializing in medicine, anesthesiology, and cardiovascular disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

5.1K

2

Diabetes

2

2

3.4K

3

Public Health

1

1

2.8K

4

Emergency Medicine

1

1

749

5

Health Policy

1

1

2.8K

Adrian D. Hrabar

×

12

Publications

5.7K

Citations

12

H-Index

YearCitations

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais,

The Lancet

2019

2.8K

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom,

The Lancet

2017

855

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch,

The Lancet

2017

749

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais,

The Lancet

2019

600

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Sean D. Pokorney, Jonathan P. Piccini, Susanna R. Stevens,

Journal of the American Heart Association

2016

196

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri,

The Lancet Infectious Diseases

2021

170

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek,

Circulation

2022

112

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

Shinya Goto, Pantep Angchaisuksiri, Jean‐Pierre Bassand,

Journal of the American Heart Association

2019

54

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner,

Diabetes Care

2021

32

A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers.

Adrian D. Hrabar, I Vodopija, André Fe,

PubMed

1978

31

Page 1